Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Cancer ReportsOpen Access

Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience

View Full Paper
Ask AI
Bookmark
Share

Authors

YCYi‐Hao ChiangMCMing‐Chih ChangKLKen‐Hong Lim

Discussion

Loading...

Member takes

Overview

Observational analysis shows daratumumab improves overall response rates in relapsed-refractory multiple myeloma, indicating possible benefits of second-line therapy.

Key Points

  • The overall response rate of daratumumab therapy reached 76.5% in 17 patients with relapsed-refractory multiple myeloma.
  • Observational case series identified a median progression-free survival of 20 months with daratumumab as second-line treatment.
  • Adverse effects of daratumumab therapy included neutropenia and pneumonia, impacting treatment outcomes.
  • Highlights the potential of daratumumab in real-world clinical application for multiple myeloma patients.

Cite This Study

Chiang et al. (2025) studied this question.

synapsesocial.com/papers/6930dc5fea1aef094cca1bf8https://doi.org/10.1002/cnr2.70367
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Cancer statistics, 20242024 · 9,500 citations